New chemo sequence aims to make pancreatic tumors operable
NCT ID NCT05825066
First seen Jun 24, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This phase 2 trial is testing whether giving two different chemotherapy regimens one after the other can shrink pancreatic tumors that are borderline or locally advanced, making them easier to remove surgically. The study enrolls 64 adults with pancreatic adenocarcinoma. Participants first receive gemcitabine plus nab-paclitaxel for one month, then switch to mFOLFIRINOX for another month, before being evaluated for surgery. The main goal is to see how many patients achieve a clean surgical margin (R0 resection).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gemcitabine, nab-paclitaxel (Abraxane), and mFOLFIRINOX (a combination of four chemotherapy drugs)
- What this could lead to
- If this sequence works, it could help shrink pancreatic tumors enough to allow more patients to have successful surgery, potentially improving survival.
- What could go wrong
- This is a small, early-phase trial with only 64 participants. The sequence is experimental and may not be more effective than standard treatment, and chemotherapy carries significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Could a simple blood test catch pancreatic cancer before It's too late?
- Scientists hunt for clues to prevent a common complication after pancreatic cancer surgery
- Immune cells armed with antibody take on pancreatic cancer
- New drug THE-0504 enters human testing for tough cancers
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers